Mesoblast Limited MESO

MESO Company Overview

Mesoblast Limited is an Australia-based regenerative medicine biotechnology company focused on developing and commercializing allogeneic cellular therapies derived from mesenchymal lineage adult stem cells. The company operates primarily in the biotechnology and biopharmaceutical industries, with a concentration on inflammatory diseases, immune-mediated conditions, and cardiovascular disorders. Mesoblast’s core platform is built around proprietary mesenchymal stromal cell (MSC) technologies designed to modulate inflammatory and immune responses. Its primary revenue and value drivers have historically been tied to product development milestones, licensing arrangements, collaborative agreements, and capital market financing rather than broad commercial product sales.

The company’s lead product candidates include remestemcel-L and rexlemestrocel-L, which have been investigated for conditions such as steroid-refractory acute graft-versus-host disease (SR-aGVHD), chronic low back pain associated with degenerative disc disease, and advanced heart failure. Mesoblast has positioned itself as a developer of off-the-shelf cellular medicines with scalable manufacturing capabilities and intellectual property surrounding mesenchymal precursor cells. Founded in 2004 and headquartered in Melbourne, the company expanded through acquisitions and licensing activity, including the acquisition of Osiris Therapeutics intellectual property assets and collaborations with major pharmaceutical companies. Mesoblast is publicly traded on the Australian Securities Exchange and over-the-counter markets in the United States.